However, global gene expression analysis has shown that HER2-positive tumours constitute a heterogeneous group3 and, despite the success, many HER2-positive tumours escape the effects of HER2 inhibition and a large portion of initial responders relapse. Here, ERBB2 is linked to neoplasm.